- Home
- FAAS vs OKYO Comparison
FAAS vs OKYO Comparison
Compare FAAS & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- OKYO
- Stock Information
- Founded
- FAAS 2021
- OKYO 2007
- Country
- FAAS Indonesia
- OKYO United Kingdom
- Employees
- FAAS N/A
- OKYO N/A
- Industry
- FAAS
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FAAS
- OKYO Health Care
- Exchange
- FAAS NYSE
- OKYO Nasdaq
- Market Cap
- FAAS 34.6M
- OKYO 37.0M
- IPO Year
- FAAS N/A
- OKYO 2022
- Fundamental
- Price
- FAAS $0.53
- OKYO $1.49
- Analyst Decision
- FAAS
- OKYO Strong Buy
- Analyst Count
- FAAS 0
- OKYO 1
- Target Price
- FAAS N/A
- OKYO $7.00
- AVG Volume (30 Days)
- FAAS 188.6K
- OKYO 192.8K
- Earning Date
- FAAS 09-17-2024
- OKYO 03-25-2025
- Dividend Yield
- FAAS N/A
- OKYO N/A
- EPS Growth
- FAAS N/A
- OKYO N/A
- EPS
- FAAS N/A
- OKYO N/A
- Revenue
- FAAS $57,730,593.00
- OKYO N/A
- Revenue This Year
- FAAS N/A
- OKYO N/A
- Revenue Next Year
- FAAS N/A
- OKYO N/A
- P/E Ratio
- FAAS N/A
- OKYO N/A
- Revenue Growth
- FAAS 38.16
- OKYO N/A
- 52 Week Low
- FAAS $0.38
- OKYO $0.81
- 52 Week High
- FAAS $12.97
- OKYO $1.90
- Technical
- Relative Strength Index (RSI)
- FAAS 47.02
- OKYO 71.84
- Support Level
- FAAS $0.47
- OKYO $1.14
- Resistance Level
- FAAS $0.59
- OKYO $1.45
- Average True Range (ATR)
- FAAS 0.08
- OKYO 0.12
- MACD
- FAAS 0.01
- OKYO 0.03
- Stochastic Oscillator
- FAAS 40.87
- OKYO 82.02
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.